Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens

Vaccine

Volumn 27, Issue 47, 2009, Pages 6605-6612

  Center, Rob J ^a   Wheatley, Adam K ^a   Campbell, Shahan M ^a   Gaeguta, Adriana J ^a   Peut, Viv ^a   Alcantara, Sheilajen ^a   Siebentritt, Carly ^a   Kent, Stephen J ^a   Purcell, Damian F J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Envelope protein; HIV 1; Vaccine

Indexed keywords

DNA VACCINE; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PRIMER DNA; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IN VITRO STUDY; MALE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HELA CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MACACA NEMESTRINA; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 70350564956     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.016     Document Type: Article

References (39)

1. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., and Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191 5 (2005) 654-665
2. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 9653 (2008) 1881-1893
3. Kelleher A.D., Puls R.L., Bebbington M., Boyle D., Ffrench R., Kent S.J., et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. Aids 20 2 (2006) 294-297
4. Dale C.J., De Rose R., Wilson K.M., Croom H.A., Thomson S., Coupar B.E.H., et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpox virus vaccines co-expressing IFNγ or IL-12. Vaccine 23 2 (2004) 188-197
5. Akahata W., Ido E., Akiyama H., Uesaka H., Enose Y., Horiuchi R., et al. DNA vaccination of macaques by a full-genome simian/human immunodeficiency virus type 1 plasmid chimera that produces non-infectious virus particles. J Gen Virol 84 8 (2003) 2237-2244
6. Wagner R., Teeuwsen V.J.P., Deml L., Notka F., Haaksma A.G.M., Jhagjhoorsingh S.S., et al. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection. Virology 245 May(1) (1998) 65-74
7. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 28 3 (2006) 255-265
8. De Rose R., Chea S., Dale C.J., Reece J., Fernandez C.S., Wilson K.M., et al. Subtype AE HIV-1 DNA and recombinant fowlpox virus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 23 16 (2005) 1949-1956
9. Theodore T.S., Englund G., Buckler-White A., Buckler C.E., Martin M.A., and Peden K.W.C. Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res Hum Retroviruses 12 3 (1996) 191-194
10. Anderson J.L., Johnson A.T., Howard J.L., and Purcell D.F.J. Both linear and discontinuous ribosome scanning are used for translation initiation from bicistronic human immunodeficiency virus type 1 Env mRNAs. J Virol 81 9 (2007) 4664-4676
11. Gao F., Morrison S.G., Robertson D.L., Thornton C.L., Craig S., Karlsson G., et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. J Virol 70 3 (1996) 1651-1667
12. Center R.J., Earl P.L., Lebowitz J., Schuck P., and Moss B. The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts. J Virol 74 10 (2000) 4448-4455
13. Center R.J., Lebowitz J., Leapman R.D., and Moss B. Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras. J Virol 78 5 (2004) 2265-2276
14. Dale C.J., De Rose R., Stratov I., Chea S., Montefiori D.C., Thomson S., et al. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J Virol 78 24 (2004) 13819-13828
15. Batten C.J., De Rose R., Wilson K.M., Agy M.B., Chea S., Stratov I., et al. Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. AIDS Res Hum Retroviruses 22 6 (2006) 580-588
16. Feltquate D.M., Heaney S., Webster R.G., and Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 158 5 (1997) 2278-2284
17. SF162P3. Vaccine 23 42 (2005) 5009-5021
18. De Rose R., Batten C.J., Smith M.Z., Fernandez C.S., Peut V., Thomson S., et al. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol 81 1 (2007) 292-300
19. De Rose R., Fernandez C.S., Smith M.Z., Batten C.J., Alcantara S., Peut V., et al. Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog 4 5 (2008) e1000055
20. Center R.J., Leapman R.D., Lebowitz J., Arthur L.O., Earl P.L., and Moss B. Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol 76 15 (2002) 7863-7867
21. Leclerc C., Deriaud E., Rojas M., and Whalen R.G. The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol 179 2 (1997) 97-106
22. Martinez V., Costagliola D., Bonduelle O., N'go N., Schnuriger A., Theodorou I., et al. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 191 12 (2005) 2053-2063
23. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78 23 (2004) 13232-13252
24. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10 4 (1994) 359-369
25. Saphire E.O., Parren P.W.H.I., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 293 5532 (2001) 1155-1159
26. Zemlin M., Klinger M., Link J., Zemlin C., Bauer K., Engler J.A., et al. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol 334 4 (2003) 733-749
27. Malenbaum S.E., Yang D., and Cheng-Mayer C. Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques. J Virol 75 19 (2001) 9287-9296
28. Polonis V.R., De Souza M.S., Chanbancherd P., Chantakulkij S., Jugsudee A., Loomis-Price L.D., et al. HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies. AIDS Res Hum Retroviruses 17 1 (2001) 69-79
29. Naganawa S., Yokoyama M., Shiino T., Suzuki T., Ishigatsubo Y., Ueda A., et al. Net positive charge of HIV-1 CRF01_AE V3 sequence regulates viral sensitivity to humoral immunity. PLoS ONE 3 9 (2008) e3206
30. Brown B.K., Darden J.M., Tovanabutra S., Oblander T., Frost J., Sanders-Buell E., et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol 79 10 (2005) 6089-6101
31. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82 23 (2008) 11651-11668
32. Pal R., Wang S., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348 2 (2006) 341-353
33. Xu R., Srivastava I.K., Kuller L., Zarkikh I., Kraft Z., Fagrouch Z., et al. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology 349 2 (2006) 276-289
34. Zhan X., Martin L.N., Slobod K.S., Coleclough C., Lockey T.D., Brown S.A., et al. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 23 46-47 (2005) 5306-5320
35. Cho M.W., Kim Y.B., Lee M.K., Gupta K.C., Ross W., Plishka R., et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J Virol 75 5 (2001) 2224-2234
36. Seaman M.S., Leblanc D.F., Grandpre L.E., Bartman M.T., Montefiori D.C., Letvin N.L., et al. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology 367 1 (2007) 175-186
37. Seaman M.S., Xu L., Beaudry K., Martin K.L., Beddall M.H., Miura A., et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79 5 (2005) 2956-2963
38. McDermott A.B., Mitchen J., Piaskowski S., De Souza I., Yant L.J., Stephany J., et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J Virol 78 6 (2004) 3140-3144
39. Verschoor E.J., Davis D., van Gils M., Koopman G., Mooij P., Oostermeijer H., et al. Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus. J Med Primatol 28 4-5 (1999) 224-232